World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
89
Citations
72395
World Ranking
12407
National Ranking
6351

Naiyer A. Rizvi publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Naiyer A. Rizvi sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 363 publications — 31st percentile

31% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Naiyer A. Rizvi D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Naiyer A. Rizvi sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 89 D-Index — 38th percentile

38% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Naiyer A. Rizvi is affiliated with Columbia University Medical Center in the United States and has an extensive publication record primarily in the field of Medicine, with a focus on Oncology and Pulmonary and Respiratory Medicine. Their research covers a broad spectrum of topics related to cancer immunotherapy, lung cancer treatments, and molecular biology.

Their recent published papers include:

  • Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial, 2021, The Lancet
  • Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial, 2020, The Lancet Oncology
  • Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer, 2020, JAMA Oncology
  • Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project, 2020, Journal for ImmunoTherapy of Cancer
  • Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response, 2020, Cancer Discovery

Naiyer A. Rizvi's frequently published venues include:

  • Cancer Research
  • Journal of Thoracic Oncology
  • Journal for ImmunoTherapy of Cancer
  • Journal of Clinical Oncology
  • Clinical Cancer Research

Collaboration forms an important part of their research output, working frequently with co-authors such as:

  • Brian S. Henick
  • Mark M. Awad
  • Justin F. Gainor
  • John V. Heymach
  • Catherine A. Shu

The main fields of study in their research are Medicine with a strong concentration on subfields including:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Immunology
  • Molecular Biology

Their primary research topics focus on:

  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Treatments and Mutations
  • Cancer Genomics and Diagnostics
  • Lung Cancer Research Studies
  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Lung Cancer Diagnosis and Treatment

Best Publications

  • Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

    H. Borghaei;L. Paz-Ares;L. Horn;D. R. Spigel

  • Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

    Naiyer A. Rizvi;Naiyer A. Rizvi;Matthew D. Hellmann;Matthew D. Hellmann;Alexandra Snyder;Alexandra Snyder;Pia Kvistborg

  • Pembrolizumab for the treatment of non-small cell lung cancer

    Edward B. Garon;Naiyer A. Rizvi;Rina Hui;Natasha Leighl

  • Nivolumab plus Ipilimumab in Advanced Melanoma

    Jedd D. Wolchok;Harriet Kluger;Margaret K. Callahan;Michael A. Postow

  • Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

    Robert M Samstein;Chung-Han Lee;Chung-Han Lee;Alexander N Shoushtari;Alexander N Shoushtari;Matthew D Hellmann;Matthew D Hellmann

  • Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

    Nicholas McGranahan;Nicholas McGranahan;Andrew J. S. Furness;Rachel Rosenthal;Sofie Ramskov

  • Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

    Naiyer A. Rizvi;Julien Mazières;David Planchard;Thomas E. Stinchcombe

  • Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

    Scott N. Gettinger;Leora Horn;Leena Gandhi;David R. Spigel

  • Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

    Diego Chowell;Luc G. T. Morris;Claud M. Grigg;Jeffrey K. Weber

  • Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

    Antoni Ribas;Omid Hamid;Adil Daud;F. Stephen Hodi

  • Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

    Matthew D. Hellmann;Naiyer A. Rizvi;Jonathan W. Goldman;Scott N. Gettinger

  • Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer

    Vincent A. Miller;Mark G. Kris;Neelain Shah;Jyoti Patel

  • Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

    Leora Horn;David R. Spigel;Everett E. Vokes;Esther Holgado

  • Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib

    Gregory J. Riely;William Pao;Duy Khanh Pham;Allan R. Li

  • Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

    Edward B. Garon;Matthew D. Hellmann;Naiyer A. Rizvi;Enric Carcereny

  • Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.

    Matthew D. Hellmann;Margaret K. Callahan;Mark M. Awad;Emiliano Calvo

  • A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy

    Marta Łuksza;Nadeem Riaz;Vladimir Makarov;Vinod P. Balachandran

  • Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

    Scott J. Antonia;Sarah B. Goldberg;Ani Sarkis Balmanoukian;Jamie E. Chaft

  • Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.

    Ahmet Sezer;Saadettin Kilickap;Mahmut Gümüş;Igor Bondarenko

  • Classification of current anticancer immunotherapies

    Lorenzo Galluzzi;Erika Vacchelli;José Manuel Bravo-San Pedro;Aitziber Buqué

Frequent Co-Authors

Mark G. Kris
Mark G. Kris Memorial Sloan Kettering Cancer Center
Matthew D. Hellmann
Matthew D. Hellmann Memorial Sloan Kettering Cancer Center
Scott J. Antonia
Scott J. Antonia Duke University
Scott N. Gettinger
Scott N. Gettinger Yale University
Julie R. Brahmer
Julie R. Brahmer Johns Hopkins University
Gregory J. Riely
Gregory J. Riely Memorial Sloan Kettering Cancer Center
Solange Peters
Solange Peters University Hospital of Lausanne
William Pao
William Pao Roche (United States)
Leora Horn
Leora Horn Vanderbilt University Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative routes to a healthcare career is becoming increasingly popular. Many students are looking for faster or more flexible pathways aside from traditional medical degrees. For example, online direct entry msn programs for non-nurses allow individuals with a non-nursing background to transition into advanced nursing roles in less time.

Those seeking a more accessible starting point may benefit from online adn programs for non nurses. These programs provide foundational nursing education, often with flexible schedules and less stringent admission requirements.

Not everyone pursuing a healthcare-related career wants to provide direct patient care. Administrative roles such as medical billing and coding are in high demand. There are numerous medical billing and coding schools online that offer accredited programs—many with financial aid options.

Prospective students worried about entrance exams can consider a lpn program no entrance exam. These options can help learners begin a healthcare career quickly and with less stress during the application process.

Best Scientists Citing Naiyer A. Rizvi

Trending Scientists

Recently Published Articles